This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
coronavirus disease | 22100 |
novel coronavirus | 19197 |
acute respiratory | 16933 |
respiratory syndrome | 13213 |
severe acute | 11214 |
public health | 10521 |
mental health | 9841 |
severe covid | 9019 |
author funder | 8631 |
granted medrxiv | 8623 |
health care | 8274 |
copyright holder | 8226 |
cord uid | 7820 |
doc id | 7819 |
version posted | 7388 |
syndrome coronavirus | 7334 |
social distancing | 7172 |
risk factors | 6938 |
clinical characteristics | 6890 |
systematic review | 6308 |
intensive care | 6270 |
made available | 5880 |
critically ill | 5878 |
united states | 5750 |
respiratory distress | 5597 |
international license | 5429 |
world health | 5377 |
health organization | 5003 |
peer review | 4932 |
confirmed cases | 4870 |
hospitalized patients | 4766 |
distress syndrome | 4676 |
medrxiv preprint | 4657 |
chest ct | 4396 |
clinical trials | 4277 |
ill patients | 4185 |
cytokine storm | 4178 |
cohort study | 4019 |
mechanical ventilation | 3987 |
healthcare workers | 3929 |
rights reserved | 3762 |
immune response | 3758 |
clinical features | 3730 |
infectious diseases | 3622 |
converting enzyme | 3494 |
patients infected | 3225 |
care unit | 3218 |
respiratory failure | 3172 |
confirmed covid | 3168 |
new york | 3092 |
increased risk | 3055 |
middle east | 3052 |
protective equipment | 3026 |
social media | 3005 |
mortality rate | 2946 |
immune system | 2918 |
clinical trial | 2840 |
infectious disease | 2790 |
coronavirus pneumonia | 2778 |
personal protective | 2777 |
general population | 2773 |
east respiratory | 2768 |
pregnant women | 2721 |
clinical course | 2712 |
disease severity | 2698 |
respiratory tract | 2664 |
severe disease | 2662 |
disease control | 2660 |
infected patients | 2636 |
case series | 2590 |
high risk | 2582 |
lung injury | 2546 |
cancer patients | 2538 |
higher risk | 2496 |
convalescent plasma | 2480 |
coronavirus infection | 2360 |
among patients | 2352 |
viral load | 2319 |
critical care | 2313 |
care workers | 2307 |
statistically significant | 2260 |
may also | 2255 |
viral infection | 2189 |
severe cases | 2186 |
viral infections | 2132 |
risk factor | 2131 |
contact tracing | 2087 |
cardiovascular disease | 2077 |
spike protein | 2071 |
fatality rate | 1999 |
incubation period | 1994 |
retrospective cohort | 1974 |
significantly higher | 1960 |
older adults | 1953 |
data collection | 1940 |
respiratory symptoms | 1935 |
nucleic acid | 1899 |
authors declare | 1897 |
informed consent | 1876 |
new coronavirus | 1872 |
sample size | 1855 |
heart failure | 1842 |
deep learning | 1833 |
immune responses | 1828 |
observational study | 1820 |
present study | 1811 |
inflammatory cytokines | 1807 |
factors associated | 1807 |
reactive protein | 1795 |
without permission | 1792 |
allowed without | 1781 |
reuse allowed | 1779 |
viral rna | 1775 |
lopinavir ritonavir | 1771 |
emergency department | 1742 |
clinical outcomes | 1735 |
epithelial cells | 1729 |
infection control | 1726 |
chain reaction | 1716 |
diabetes mellitus | 1714 |
sars coronavirus | 1710 |
posted may | 1699 |
previous studies | 1697 |
inflammatory response | 1695 |
health system | 1686 |
polymerase chain | 1655 |
case report | 1638 |
logistic regression | 1627 |
medical staff | 1626 |
infected pneumonia | 1616 |
global health | 1613 |
symptom onset | 1613 |
computed tomography | 1606 |
clinical practice | 1602 |
tested positive | 1599 |
first case | 1598 |
control measures | 1571 |
hong kong | 1566 |
retrospective study | 1562 |
patients admitted | 1553 |
control group | 1547 |
total number | 1541 |
hospital admission | 1537 |
south korea | 1519 |
psychological distress | 1518 |
machine learning | 1505 |
national health | 1494 |
case fatality | 1483 |
hubei province | 1475 |
ct scan | 1473 |
global pandemic | 1446 |
years old | 1437 |
health services | 1422 |
pulmonary embolism | 1422 |
family members | 1408 |
blood pressure | 1401 |
corona virus | 1400 |
physical distancing | 1390 |
significant difference | 1379 |
randomized controlled | 1378 |
health emergency | 1377 |
positive patients | 1370 |
per day | 1362 |
angiotensin ii | 1354 |
mortality rates | 1349 |
controlled trial | 1348 |
myocardial infarction | 1342 |
patients hospitalized | 1341 |
health systems | 1333 |
ct findings | 1331 |
nervous system | 1325 |
icu admission | 1321 |
new cases | 1320 |
suspected covid | 1319 |
innate immune | 1311 |
oxygen saturation | 1311 |
virus infection | 1308 |
physical activity | 1296 |
primary care | 1289 |
en el | 1265 |
york city | 1262 |
descriptive study | 1254 |
two groups | 1249 |
organ failure | 1244 |
posted june | 1240 |
respiratory disease | 1239 |
heart disease | 1234 |
severe patients | 1230 |
reproduction number | 1227 |
ace expression | 1218 |
pulmonary disease | 1215 |
kidney disease | 1213 |
influenza virus | 1208 |
high levels | 1199 |
healthcare professionals | 1189 |
patient care | 1186 |
patients may | 1185 |
performed using | 1175 |
endothelial cells | 1174 |
healthcare system | 1172 |
randomized clinical | 1170 |
kidney injury | 1164 |
psychological impact | 1161 |
least one | 1160 |
median age | 1149 |
upper respiratory | 1148 |
acute lung | 1146 |
transmission dynamics | 1145 |
significant differences | 1138 |
venous thromboembolism | 1134 |
data analysis | 1134 |
test results | 1129 |
air pollution | 1127 |
patients without | 1124 |
icu patients | 1123 |
close contact | 1120 |
viral replication | 1120 |
myocardial injury | 1119 |
type i | 1119 |
study period | 1117 |
current study | 1115 |
virus disease | 1114 |
coronavirus infections | 1114 |
adverse events | 1113 |
patients treated | 1110 |
many countries | 1109 |
disease progression | 1107 |
recent study | 1102 |
cov infection | 1100 |
immune cells | 1097 |
cardiac injury | 1095 |
time series | 1086 |
type diabetes | 1085 |
mean age | 1082 |
current pandemic | 1081 |
large number | 1080 |
clinical symptoms | 1079 |
viral pneumonia | 1077 |
important role | 1072 |
clinical data | 1070 |
early stage | 1068 |
liver injury | 1066 |
may lead | 1062 |
acute kidney | 1059 |
cytokine release | 1058 |
age groups | 1057 |
coronavirus outbreak | 1056 |
human coronavirus | 1055 |
nan doi | 1050 |
sectional study | 1050 |
higher levels | 1050 |
china clinical | 1044 |
case reports | 1042 |
coronavirus pandemic | 1041 |
age group | 1037 |
social isolation | 1031 |
adult inpatients | 1029 |
infected individuals | 1028 |
ct images | 1026 |
transplant recipients | 1024 |
host cell | 1022 |
severe illness | 1017 |
severe pneumonia | 1009 |
even though | 1006 |
distancing measures | 1000 |
face masks | 997 |
clinical manifestations | 995 |
viral shedding | 983 |
antiviral activity | 980 |
posted july | 978 |
nasopharyngeal swab | 978 |
saudi arabia | 972 |
regression analysis | 968 |
confidence interval | 968 |
health crisis | 967 |
critical illness | 967 |
gastrointestinal symptoms | 967 |
artificial intelligence | 964 |
depressive symptoms | 964 |
preventive measures | 962 |
infection prevention | 961 |
ace receptor | 961 |
lung cancer | 960 |
social support | 958 |
creative commons | 958 |
patients receiving | 956 |
clinical studies | 952 |
peripheral blood | 950 |
chronic obstructive | 949 |
ray images | 948 |
health commission | 947 |
pcr testing | 946 |
clinical presentation | 945 |
healthcare systems | 942 |
standard deviation | 940 |
posted september | 940 |
ng ml | 940 |
health professionals | 938 |
another study | 938 |
care units | 936 |
health conditions | 934 |
study clinical | 930 |
positive cases | 929 |
ct scans | 925 |
medical care | 924 |
respiratory infections | 922 |
population density | 920 |
severe respiratory | 919 |
rheumatoid arthritis | 919 |
ethics committee | 917 |
respiratory infection | 915 |
stem cells | 915 |
lung disease | 914 |
income countries | 913 |
hospital stay | 913 |
two patients | 913 |
adverse effects | 911 |
one patient | 910 |
statistical analysis | 907 |
obstructive pulmonary | 906 |
hospital mortality | 905 |
health problems | 904 |
situation report | 903 |
health outcomes | 903 |
side effects | 901 |
poor prognosis | 896 |
study design | 895 |
million people | 894 |
observational studies | 893 |
health workers | 892 |
less likely | 892 |
dry cough | 892 |
medical records | 890 |
infection rate | 889 |
sore throat | 887 |
within days | 887 |
nursing homes | 883 |
angiotensin system | 883 |
adult patients | 883 |
glass opacities | 881 |
septic shock | 881 |
continuous variables | 872 |
significantly associated | 871 |
los pacientes | 869 |
cell entry | 869 |
also found | 867 |
healthcare providers | 864 |
hospitalized covid | 861 |
hand hygiene | 859 |
ill covid | 856 |
current covid | 856 |
will need | 855 |
lymphocyte count | 852 |
united kingdom | 852 |
reported cases | 852 |
available data | 851 |
categorical variables | 851 |
pcr test | 848 |
care providers | 843 |
asymptomatic patients | 843 |
older people | 841 |
gene expression | 839 |
systematic reviews | 838 |
competing interests | 837 |
liver disease | 837 |
pediatric patients | 834 |
angiotensin converting | 834 |
host cells | 832 |
clinical management | 832 |
lower respiratory | 830 |
multiple organ | 829 |
supply chain | 829 |
palliative care | 825 |
older age | 821 |
early stages | 818 |
literature review | 816 |
ebola virus | 814 |
risk assessment | 812 |
interim guidance | 810 |
several studies | 809 |
decision making | 809 |
ischemic stroke | 805 |
controlled trials | 804 |
patients presenting | 804 |
supplementary table | 800 |
pacientes con | 798 |
operating room | 795 |
mild symptoms | 793 |
release syndrome | 792 |
march th | 788 |
respiratory rate | 787 |
mg dl | 784 |
two weeks | 781 |
elderly patients | 780 |
receptor blockers | 777 |
chinese center | 777 |
see table | 776 |
care system | 776 |
oxygen therapy | 774 |
higher mortality | 772 |
one study | 772 |
significantly lower | 772 |
necrosis factor | 770 |
regression model | 770 |
also reported | 768 |
medical conditions | 763 |
ct imaging | 761 |
nk cells | 760 |
invasive mechanical | 758 |
outcomes among | 757 |
patients requiring | 757 |
supplementary material | 756 |
chronic kidney | 755 |
herd immunity | 751 |
study showed | 751 |
blood cell | 748 |
sars cov | 748 |
may help | 748 |
membrane oxygenation | 747 |
viral entry | 746 |
publicly available | 746 |
different countries | 745 |
suspected cases | 744 |
confirmed case | 743 |
review board | 742 |
recent studies | 740 |
receptor binding | 737 |
neural network | 736 |
extracorporeal membrane | 734 |
general public | 734 |
institutional review | 731 |
vertical transmission | 730 |
central nervous | 730 |
face mask | 730 |
wide range | 729 |
antiviral drugs | 729 |
statistical significance | 727 |
posted october | 726 |
reverse transcription | 724 |
health authorities | 723 |
white blood | 723 |
mesenchymal stem | 722 |
widely used | 721 |
springer nature | 720 |
close contacts | 720 |
among covid | 717 |
health status | 717 |
severe coronavirus | 716 |
dimer levels | 715 |
infected cases | 714 |
human coronaviruses | 713 |
medical students | 712 |
older patients | 712 |
odds ratio | 711 |
epidemiological characteristics | 710 |
published maps | 709 |
institutional affiliations | 709 |
remains neutral | 709 |
jurisdictional claims | 709 |
human transmission | 708 |
nature remains | 708 |
respiratory support | 708 |
european countries | 706 |
important lessons | 705 |
lactate dehydrogenase | 704 |
may increase | 700 |
breast cancer | 699 |
neural networks | 698 |
coronary artery | 696 |
inclusion criteria | 694 |
cardiovascular diseases | 692 |
clinical improvement | 692 |
lessons learned | 691 |
invasive ventilation | 690 |
oxidative stress | 688 |
will also | 687 |
case study | 686 |
may cause | 686 |
online survey | 681 |
animal models | 678 |
risk perception | 678 |
spike glycoprotein | 677 |
inflammatory markers | 675 |
many patients | 674 |
infected people | 674 |
open access | 673 |
death rate | 673 |
proinflammatory cytokines | 672 |
ground glass | 669 |
laboratory findings | 669 |
prospective cohort | 668 |
high mortality | 667 |
health measures | 667 |
table shows | 666 |
early phase | 665 |
confidence intervals | 665 |
future research | 663 |
respiratory droplets | 662 |
real time | 661 |
note springer | 660 |
medical history | 660 |
high level | 660 |
time period | 660 |
community transmission | 660 |
chronic diseases | 658 |
disease course | 658 |
antibody responses | 657 |
respiratory viruses | 656 |
neutralizing antibodies | 655 |
rna polymerase | 655 |
critical covid | 653 |
high prevalence | 649 |
commonly used | 647 |
traditional chinese | 646 |
respiratory diseases | 645 |
american college | 644 |
included studies | 643 |
basic reproduction | 642 |
chinese medicine | 642 |
kidney transplant | 642 |
severely ill | 641 |
lung ultrasound | 641 |
disease transmission | 639 |
air quality | 638 |
symptomatic patients | 637 |
study population | 637 |
task force | 637 |
viral clearance | 636 |
treat covid | 633 |
neurological manifestations | 631 |
common symptoms | 631 |
developing countries | 630 |
urgent need | 630 |
term care | 630 |
patients received | 629 |
supply chains | 627 |
national institute | 625 |
linear regression | 624 |
patients undergoing | 623 |
monoclonal antibody | 622 |
growth rate | 622 |
tumor necrosis | 622 |
long term | 622 |
covid patients | 621 |
coronavirus sars | 621 |
posted august | 619 |
mass index | 619 |
thrombotic complications | 618 |
organ dysfunction | 618 |
interquartile range | 617 |
mg kg | 616 |
effective treatment | 616 |
pandemic influenza | 615 |
adaptive immune | 615 |
respiratory syncytial | 614 |
regression models | 614 |
body temperature | 612 |
statistical analyses | 611 |
body mass | 610 |
stem cell | 609 |
results showed | 609 |
nursing home | 609 |
syncytial virus | 608 |
binding domain | 608 |
south africa | 606 |
sars outbreak | 605 |
laboratory tests | 605 |
may result | 605 |
amino acid | 605 |
day mortality | 604 |
second wave | 604 |
different types | 602 |
severe symptoms | 602 |
fatality rates | 601 |
analysis showed | 600 |
mortality among | 600 |
influenza pandemic | 599 |
respiratory illness | 598 |
future studies | 598 |
intravascular coagulation | 597 |
medical center | 595 |
increased mortality | 594 |
acute myocardial | 594 |
climate change | 591 |
northern italy | 591 |
missing data | 591 |
baseline characteristics | 586 |
food insecurity | 586 |
acute phase | 585 |
health interventions | 585 |
disseminated intravascular | 585 |
care facilities | 585 |
infection rates | 584 |
adverse outcomes | 583 |
modelling study | 583 |
cruise ship | 583 |
imaging features | 582 |
data set | 582 |
will help | 581 |
convolutional neural | 580 |
april th | 580 |
potential therapeutic | 579 |
platelet count | 577 |
may contribute | 577 |
financial support | 576 |
university hospital | 575 |
heart rate | 575 |
cardiovascular system | 574 |
low risk | 573 |
travel restrictions | 573 |
drug administration | 573 |
sleep quality | 572 |
mortality risk | 571 |
protease inhibitor | 571 |
treating covid | 571 |
several limitations | 571 |
disease caused | 570 |
reproductive number | 569 |
disease outbreak | 568 |
demographic characteristics | 568 |
human ace | 567 |
relative humidity | 567 |
health service | 565 |
dendritic cells | 565 |
viral loads | 565 |
nasal cannula | 562 |
aged years | 562 |
study found | 562 |
pao fio | 560 |
systemic inflammation | 560 |
treatment options | 560 |
endothelial cell | 559 |
will likely | 559 |
cell count | 559 |
patients showed | 558 |
written informed | 556 |
medical education | 556 |
study conducted | 555 |
pulmonary fibrosis | 554 |
asymptomatic cases | 554 |
ace inhibitors | 552 |
supplemental oxygen | 552 |
abdominal pain | 551 |
regarding covid | 550 |
small sample | 549 |
contracting covid | 549 |
elective surgery | 548 |
type ii | 548 |
respiratory system | 546 |
blood glucose | 545 |
anxiety disorder | 544 |
acquired pneumonia | 544 |
pandemic date | 543 |
pharmaceutical interventions | 543 |
vaccine development | 543 |
plasma therapy | 543 |
care systems | 543 |
patients will | 543 |
vital signs | 542 |
multiple sclerosis | 542 |
potential risk | 541 |
first reported | 540 |
primary outcome | 540 |
sir model | 539 |
tract infections | 539 |
surgical masks | 539 |
main protease | 539 |
sensitivity analysis | 537 |
lockdown measures | 536 |
mental disorders | 536 |
icu beds | 536 |
innate immunity | 534 |
per capita | 534 |
accepted article | 534 |
anxiety symptoms | 534 |
wuhan city | 533 |
nasopharyngeal swabs | 533 |
medical resources | 532 |
endothelial dysfunction | 531 |
sars patients | 530 |
mild covid | 529 |
clinical research | 529 |
rapid review | 529 |
study also | 528 |
imaging findings | 526 |
cases per | 526 |
surgical procedures | 525 |
critical cases | 525 |
inflammatory responses | 524 |
person transmission | 523 |
stress disorder | 523 |
angiotensin receptor | 523 |
en pacientes | 523 |
cardiac arrest | 521 |
pneumonia outbreak | 521 |
pathological findings | 521 |
electronic medical | 520 |
better understand | 519 |
three patients | 518 |
among people | 518 |
moderate covid | 518 |
transmission rate | 518 |
food security | 517 |
alveolar damage | 516 |
much higher | 515 |
left ventricular | 515 |
study group | 514 |
atrial fibrillation | 512 |
supportive care | 512 |
early detection | 511 |
greater risk | 511 |
consensus statement | 511 |
patients diagnosed | 510 |
early transmission | 510 |
small number | 510 |
may play | 510 |
rapid spread | 510 |
risk patients | 510 |
elevated levels | 510 |
disease prevention | 509 |
disease patients | 509 |
rna viruses | 508 |
coronavirus covid | 508 |
higher rates | 507 |
cell responses | 507 |
per million | 507 |
viral transmission | 507 |
perceived stress | 506 |
care professionals | 505 |
included patients | 505 |
retrospective analysis | 505 |
en los | 504 |
ct features | 504 |
protective measures | 503 |
negative pressure | 502 |
traumatic stress | 502 |
median time | 502 |
inflammatory bowel | 502 |
transfer learning | 502 |
posted april | 501 |
first step | 500 |
emergency room | 500 |
will continue | 500 |
direct contact | 499 |
lockdown period | 499 |
care services | 499 |
immune function | 498 |
critical patients | 498 |
cd cd | 497 |
coping strategies | 496 |
commons attribution | 495 |
north america | 495 |
inflammatory cytokine | 495 |
pilot study | 493 |
study reported | 493 |
international concern | 493 |
two cases | 492 |
chest pain | 492 |
th march | 492 |
also observed | 491 |
every day | 491 |
may provide | 491 |
cerebrovascular disease | 491 |
independent risk | 491 |
emergency response | 490 |
first covid | 489 |
cell types | 488 |
ang ii | 488 |
viral particles | 488 |
surgical mask | 488 |
nitric oxide | 487 |
observational cohort | 487 |
substance use | 487 |
current evidence | 486 |
diffuse alveolar | 485 |
hospital beds | 485 |
significantly increased | 485 |
studies reported | 484 |
med doi | 483 |
exact test | 482 |
submitted work | 482 |
time reverse | 482 |
drug repurposing | 481 |
adipose tissue | 481 |
negative impact | 481 |
generalized anxiety | 480 |
macrophage activation | 480 |
single center | 480 |
data suggest | 480 |
physical health | 480 |
results suggest | 480 |
inflammatory syndrome | 478 |
liver function | 478 |
lung tissue | 478 |
reverse transcriptase | 478 |
chest computed | 478 |
hospital death | 477 |
qt interval | 477 |
artery disease | 477 |
ethical approval | 476 |
among health | 476 |
ncov infection | 476 |
people living | 475 |
highly contagious | 474 |
generating procedures | 474 |
poor outcomes | 474 |
data collected | 474 |
also showed | 473 |
ace receptors | 473 |
negative results | 473 |
bat origin | 473 |
findings suggest | 473 |
mild cases | 472 |
young adults | 471 |
mortality due | 471 |
pg ml | 470 |
natural killer | 470 |
disease outbreaks | 469 |
mild disease | 469 |
virus transmission | 469 |
policy makers | 468 |
significant increase | 468 |
results show | 467 |
will require | 466 |
glass opacity | 466 |
deceased patients | 466 |
corresponding author | 465 |
predictive value | 465 |
clinical outcome | 465 |
severe sars | 462 |
staff members | 462 |
cohort studies | 461 |
common cold | 461 |
randomised controlled | 461 |
european society | 461 |
key role | 460 |
among others | 460 |
aldosterone system | 460 |
exclusion criteria | 459 |
current situation | 458 |
room air | 457 |
african americans | 456 |
lymphocyte ratio | 456 |
positive test | 456 |
pandemic covid | 455 |
infection may | 455 |
preliminary report | 454 |
information regarding | 454 |
posttraumatic stress | 454 |
higher prevalence | 453 |
neurological symptoms | 453 |
normal range | 452 |
urgently needed | 451 |
acute care | 451 |
patient population | 450 |
respiratory viral | 450 |
test result | 450 |
descriptive statistics | 450 |
many people | 450 |
big data | 450 |
physical examination | 449 |
also known | 448 |
emergency use | 447 |
one case | 447 |
control study | 447 |
clinical evidence | 447 |
worse outcomes | 446 |
sectional survey | 446 |
currently available | 445 |
evidence suggests | 445 |
serine protease | 445 |
antiviral therapy | 444 |
previous study | 444 |
infection risk | 443 |
young people | 443 |
first time | 443 |
laboratory testing | 443 |
pandemic will | 442 |
enzyme inhibitors | 442 |
emergency departments | 442 |
positive covid | 441 |
collected data | 441 |
significantly different | 441 |
vast majority | 440 |
family cluster | 440 |
hand washing | 440 |
diagnostic tests | 440 |
may need | 439 |
days later | 439 |
johns hopkins | 439 |
relatively low | 438 |
bone marrow | 438 |
significant association | 438 |
pandemic response | 438 |
pleural effusion | 437 |
early diagnosis | 436 |
monoclonal antibodies | 436 |
cancer care | 436 |
medical treatment | 436 |
within hours | 435 |
chest radiography | 434 |
dependent rna | 434 |
recently published | 434 |
functional receptor | 434 |
healthcare personnel | 433 |
coagulation parameters | 432 |
lupus erythematosus | 432 |
containment measures | 432 |
lower risk | 431 |
crucial role | 431 |
growth factor | 431 |
mathematical model | 430 |
multicenter study | 430 |
school closures | 430 |
across countries | 430 |
compassionate use | 429 |
emerging infectious | 429 |
potential role | 429 |
hospital discharge | 429 |
coronavirus spike | 428 |
narrative review | 427 |
may occur | 427 |
radiological findings | 427 |
african countries | 426 |
bcg vaccination | 426 |
among healthcare | 426 |
old man | 425 |
replacement therapy | 424 |
electronic health | 424 |
acute coronary | 424 |
renal failure | 423 |
like symptoms | 423 |
associated pneumonia | 423 |
severe group | 423 |
thrombotic events | 423 |
study covid | 422 |
determine whether | 422 |
data regarding | 422 |
mental illness | 421 |
available online | 421 |
familial cluster | 421 |
positive results | 420 |
induced lung | 420 |
vulnerable populations | 420 |
mitigation strategies | 420 |
receptor ace | 419 |
bowel disease | 419 |
first cases | 419 |
outbreak associated | 418 |
airborne transmission | 418 |
prospective study | 418 |
chest imaging | 418 |
serum levels | 417 |
tract infection | 417 |
human immunodeficiency | 416 |
exponential growth | 416 |
related deaths | 415 |
twice daily | 415 |
patients presented | 415 |
disease spread | 415 |
mechanically ventilated | 414 |
systemic inflammatory | 414 |
por covid | 414 |
asymptomatic carriers | 414 |
human respiratory | 413 |
con covid | 413 |
risk stratification | 412 |
molecular docking | 412 |
two different | 412 |
false negative | 411 |
immunodeficiency virus | 411 |
infected person | 411 |
vein thrombosis | 411 |
medical workers | 410 |
highest number | 410 |
higher proportion | 409 |
assessed using | 409 |
retrospective case | 409 |
first wave | 408 |
posted november | 408 |
neutrophil extracellular | 408 |
nlrp inflammasome | 407 |
structural proteins | 407 |
drug discovery | 407 |
previously reported | 407 |
per week | 406 |
wuhan clinical | 406 |
confirmed sars | 405 |
lung involvement | 405 |
infection among | 404 |
one hand | 404 |
severe infection | 404 |
death rates | 404 |
endotracheal intubation | 404 |
clinical care | 403 |
acute pulmonary | 403 |
closely related | 403 |
considered statistically | 403 |
study protocol | 402 |
kawasaki disease | 402 |
total population | 402 |
times higher | 402 |
home orders | 401 |
flow nasal | 401 |
pandemic may | 401 |
covid pandemic | 401 |
cumulative number | 400 |
differential diagnosis | 400 |
health research | 400 |
better understanding | 400 |
scientific community | 400 |
hospitalised patients | 399 |
increased levels | 399 |
new covid | 399 |
first two | 399 |
male sex | 399 |
probable bat | 399 |
multisystem inflammatory | 399 |
therapeutic options | 399 |
respiratory specimens | 399 |
systemic lupus | 397 |
corticosteroid treatment | 396 |
bronchoalveolar lavage | 396 |
death toll | 396 |
virus replication | 395 |
new zealand | 395 |
poor outcome | 395 |
cause mortality | 394 |
selection bias | 394 |
epidemiological data | 393 |
severely affected | 393 |
pcr tests | 393 |
clinically proven | 393 |
remains unclear | 392 |
cell therapy | 392 |
prone positioning | 392 |
patient outcomes | 392 |
chloroquine phosphate | 392 |
mainland china | 392 |
african american | 391 |
acei arb | 391 |
clinical findings | 391 |
blood cells | 390 |
tested negative | 390 |
healthcare settings | 390 |
underlying diseases | 390 |
might also | 389 |
american society | 389 |
risk group | 388 |
first week | 388 |
activation syndrome | 388 |
data available | 388 |
rural areas | 388 |
propensity score | 388 |
four patients | 387 |
diamond princess | 387 |
blood samples | 387 |
ii receptor | 386 |
intravenous immunoglobulin | 386 |
care homes | 386 |
five patients | 386 |
first study | 385 |
respiratory virus | 385 |
united nations | 385 |
autoimmune diseases | 384 |
disease covid | 383 |
economic impact | 383 |
cases reported | 383 |
health insurance | 383 |
hospital admissions | 382 |
independently associated | 382 |
taken together | 382 |
may th | 382 |
healthy controls | 382 |
th april | 381 |
significant reduction | 380 |
host immune | 380 |
olfactory dysfunction | 380 |
time rt | 380 |
demographic data | 380 |
neurologic manifestations | 380 |
tertiary care | 380 |
clinical signs | 380 |
abnormal coagulation | 380 |
respondents reported | 379 |
first days | 379 |
health issues | 379 |
standard care | 378 |
square test | 378 |
cell surface | 378 |
fake news | 378 |
blood group | 378 |
infected cells | 378 |
bacterial infection | 378 |
among children | 377 |
final manuscript | 377 |
entry depends | 377 |
lung damage | 377 |
extracellular traps | 377 |
patients affected | 376 |
team members | 376 |
i interferon | 376 |
prevention measures | 375 |
storm syndromes | 375 |
pneumonia associated | 375 |
gender differences | 375 |
china covid | 375 |
risk groups | 374 |
high incidence | 374 |
commons licence | 373 |
cytokine production | 373 |
working group | 373 |
immune cell | 373 |
gold standard | 372 |
healthcare facilities | 372 |
imported cases | 372 |
may affect | 372 |
patient management | 371 |
increasing number | 371 |
limited number | 371 |
negative rt | 370 |
incidence rate | 370 |
ventilated patients | 370 |
severe critical | 370 |
active cases | 369 |
seasonal influenza | 369 |
associated factors | 369 |
million cases | 369 |
transcription polymerase | 369 |
study aimed | 369 |
sars epidemic | 368 |
likert scale | 368 |
antiviral drug | 368 |
spread rapidly | 368 |
available evidence | 368 |
healthcare services | 368 |
health literacy | 368 |
health consequences | 368 |
seir model | 367 |
low levels | 367 |
expert consensus | 366 |
response rate | 366 |
proven protease | 366 |
relatively small | 366 |
related coronavirus | 366 |
laboratory data | 366 |
gi symptoms | 366 |
also used | 366 |
coronavirus diseases | 365 |
chronic disease | 365 |
lung function | 365 |
loved ones | 364 |
health information | 364 |
coronary heart | 364 |
nationwide analysis | 364 |
consider cytokine | 363 |
life expectancy | 363 |
social distance | 363 |
data sets | 363 |
two studies | 363 |
por el | 362 |
financial relationships | 362 |
asymptomatic individuals | 362 |
antiviral agents | 362 |
total score | 361 |
may explain | 361 |
rapidly evolving | 361 |
venous thrombosis | 361 |
may require | 361 |
deep vein | 361 |
serial interval | 360 |
phase ii | 360 |
among hospitalized | 360 |
general hospital | 359 |
rapidly spread | 359 |
internal medicine | 359 |
troponin i | 359 |
authors contributed | 359 |
days prior | 358 |
short period | 358 |
thromboembolic events | 358 |
study participants | 357 |
throat swab | 357 |
limited data | 357 |
also associated | 357 |
study using | 357 |
protective effect | 356 |
se recomienda | 356 |
well known | 356 |
molecular weight | 356 |
three times | 356 |
hypercoagulable state | 356 |
pandemic period | 355 |
prothrombin time | 355 |
precautionary measures | 355 |
con el | 355 |
rheumatic diseases | 355 |
scientific evidence | 354 |
virus spread | 354 |
medical personnel | 353 |
antiviral treatment | 353 |
lower levels | 353 |
phase iii | 353 |
potential covid | 353 |
infect dis | 353 |
patients died | 353 |
old male | 352 |
three days | 352 |
mitigation measures | 351 |
chronic conditions | 351 |
significantly reduced | 351 |
critical role | 351 |
igg antibodies | 350 |
affected countries | 350 |
calculated using | 350 |
prostate cancer | 350 |
high rate | 350 |
average number | 349 |
short time | 349 |
based study | 349 |
point likert | 349 |
saharan africa | 348 |
media briefing | 348 |
protease inhibitors | 348 |
eye protection | 348 |
weight heparin | 347 |
radiation therapy | 347 |
mental status | 347 |
center study | 347 |
gastrointestinal tract | 347 |
testing positive | 347 |
higher level | 347 |
tissue damage | 346 |
rna virus | 346 |
data sources | 346 |
underlying health | 345 |
stress symptoms | 345 |
confirmed patients | 345 |
higher scores | 344 |
treatment strategies | 344 |
inflammatory drugs | 344 |
study will | 344 |
renal function | 344 |
first confirmed | 343 |
phase i | 343 |
many cases | 343 |
less severe | 343 |
risk management | 343 |
lung inflammation | 343 |
socioeconomic status | 343 |
patients reported | 343 |
clinical severity | 343 |
public transport | 342 |
multivariate analysis | 342 |
like protease | 342 |
deaths per | 342 |
chest radiograph | 342 |
without covid | 342 |
developing severe | 342 |
virus infections | 341 |
high rates | 341 |
diagnostic accuracy | 341 |
across different | 340 |
university students | 340 |
higher incidence | 340 |
health response | 339 |
acute stroke | 339 |
mg twice | 339 |
previously described | 339 |
transplant patients | 339 |
measures taken | 339 |
literature search | 338 |
york times | 338 |
high number | 338 |
near future | 338 |
randomized trial | 337 |
practice guidelines | 337 |
suspected patients | 337 |
studies showed | 337 |
interstitial pneumonia | 336 |
care medicine | 336 |
cutaneous manifestations | 336 |
novel virus | 336 |
body weight | 336 |
longitudinal study | 336 |
prognostic factors | 335 |
participants reported | 335 |
neutralizing antibody | 335 |
environmental factors | 335 |
pneumonia cases | 334 |
severe forms | 334 |
health organisation | 334 |
coronavirus indicating | 334 |
recovered patients | 334 |
organ damage | 334 |
target cells | 333 |
therapeutic strategies | 333 |
pulmonary edema | 333 |
plasminogen activator | 333 |
may reduce | 333 |
ace protein | 332 |
develop severe | 332 |
regression analyses | 332 |
highest risk | 332 |
patients suffering | 332 |
highly expressed | 332 |
one month | 332 |
analyzed using | 331 |
limited resources | 331 |
testing capacity | 331 |
signaling pathway | 331 |
patients compared | 330 |
host response | 330 |
combination therapy | 329 |
cardiovascular complications | 329 |
time points | 329 |
cell membrane | 329 |
acute cardiac | 328 |
travel history | 328 |
reported covid | 328 |
oral transmission | 327 |
recovery rate | 327 |
health emergencies | 327 |
clinical specimens | 327 |
positively correlated | 327 |
scoping review | 327 |
dis doi | 326 |
health policy | 326 |
clinical study | 326 |
right ventricular | 326 |
tissue distribution | 326 |
social networks | 326 |
qt prolongation | 326 |
model parameters | 326 |
human health | 325 |
higher rate | 325 |
disease clinical | 325 |
per minute | 324 |
positive sars | 324 |
relatively high | 324 |
cell rna | 323 |
also important | 323 |
resource allocation | 323 |
three months | 323 |
urban areas | 323 |
daily life | 323 |
renal disease | 323 |
proposed model | 323 |
average age | 322 |
worth noting | 322 |
antibody response | 322 |
dependent variable | 321 |
alveolar epithelial | 321 |
young children | 321 |
th day | 321 |
social determinants | 321 |
latin america | 321 |
neutrophil count | 321 |
elderly people | 321 |
drug interactions | 320 |
human mobility | 320 |
beneficial effects | 320 |
magnetic resonance | 320 |
national institutes | 320 |
requiring mechanical | 320 |
diagnostic testing | 319 |
one week | 319 |
several countries | 319 |
treating patients | 318 |
access article | 318 |
cell activation | 318 |
article distributed | 318 |
renal replacement | 318 |
transplant recipient | 317 |
potential impact | 317 |
opening remarks | 317 |
pneumonia patients | 317 |
alanine aminotransferase | 317 |
least two | 317 |
adults hospitalized | 317 |
pcr results | 317 |
ncov pneumonia | 317 |
will provide | 317 |
communicable diseases | 317 |
related symptoms | 316 |
face shield | 316 |
among older | 316 |
cumulative incidence | 316 |
neurological complications | 316 |
laboratory results | 316 |
domestic violence | 315 |
study included | 315 |
towards covid | 315 |
significant impact | 315 |
diabetic patients | 315 |
health questionnaire | 315 |
long time | 314 |
health officials | 314 |
solid organ | 314 |
previous research | 314 |
overall mortality | 313 |
infected persons | 313 |
patients developed | 313 |
psychological problems | 313 |
virus origins | 312 |
patient health | 312 |
ongoing covid | 312 |
severe outcomes | 312 |
health concern | 312 |
data extraction | 312 |
lung diseases | 312 |
inflammatory mediators | 311 |
patients included | 311 |
mg day | 311 |
blood vessels | 311 |
whole blood | 311 |
become infected | 311 |
spectrum antiviral | 311 |
research ethics | 311 |
treated patients | 310 |
higher education | 310 |
original author | 310 |
bacterial infections | 310 |
pregnant patients | 310 |
six patients | 309 |
acute ischemic | 309 |
transmission potential | 309 |
advanced age | 309 |
publication bias | 309 |
relative risk | 308 |
cell death | 308 |
using data | 308 |
lombardy region | 308 |
best practices | 308 |
ill icu | 308 |
high sensitivity | 307 |
patients dying | 307 |
positive rate | 307 |
chronic respiratory | 307 |
readily available | 307 |
much lower | 307 |
zika virus | 306 |
management strategies | 306 |
vascular endothelial | 306 |
chronic liver | 306 |
corticosteroid therapy | 306 |
pneumonia caused | 306 |
asymptomatic infection | 306 |
spike proteins | 305 |
care delivery | 305 |
th may | 305 |
two days | 305 |
use authorization | 305 |
nk cell | 305 |
crisis management | 305 |
daily new | 304 |
response team | 304 |
viral genome | 304 |
initial stage | 304 |
creatine kinase | 304 |
lower mortality | 304 |
time course | 304 |
including covid | 304 |
arterial hypertension | 303 |
scoring system | 303 |
asymptomatic carrier | 303 |
acid test | 303 |
face shields | 303 |
health doi | 303 |
perceived risk | 303 |
affected patients | 303 |
future pandemics | 303 |
short term | 303 |
prone position | 303 |
sex differences | 303 |
avian influenza | 303 |
final version | 302 |
negative patients | 302 |
clinical status | 302 |
pandemic situation | 302 |
associated coronavirus | 302 |
vulnerable groups | 302 |
potential treatment | 302 |
viral diseases | 302 |
results indicate | 302 |
coronavirus cases | 302 |
covid infection | 302 |
cl pro | 301 |
positive correlation | 301 |
alveolar macrophages | 301 |
surgical care | 301 |
washington state | 301 |
system inhibitors | 300 |
healthy individuals | 300 |
antiphospholipid antibodies | 300 |
sample collection | 300 |
angiotensinconverting enzyme | 300 |
cardiac troponin | 300 |
million confirmed | 300 |
data will | 300 |
based approach | 299 |
risk score | 299 |
antiviral effects | 299 |
tissue factor | 299 |
disease burden | 299 |
mouse model | 298 |
psychological health | 298 |
ongoing pandemic | 298 |
presenting characteristics | 298 |
healthcare staff | 298 |
stranded rna | 298 |
mathematical models | 298 |
like receptor | 298 |
medical research | 298 |
consecutive patients | 298 |
front line | 298 |
aspartate aminotransferase | 298 |
seven days | 298 |
population size | 297 |
elective surgeries | 297 |
control strategies | 297 |
full text | 297 |
many studies | 297 |
media platforms | 297 |
odds ratios | 297 |
viral respiratory | 297 |
positive rt | 297 |
nucleocapsid protein | 296 |
para el | 296 |
case numbers | 296 |
membrane fusion | 296 |
coronavirus associated | 296 |
bacterial pneumonia | 295 |
demographic variables | 295 |
blood tests | 295 |
air pollutants | 295 |
organ transplant | 294 |
deaths worldwide | 294 |
high school | 294 |
new virus | 294 |
wearing masks | 294 |
excess mortality | 294 |
time spent | 293 |
human body | 293 |
personal protection | 293 |
partial pressure | 293 |
correlation coefficient | 293 |
virus entry | 293 |
two months | 293 |
retrospective observational | 293 |
liver transplant | 293 |
genomic characterisation | 292 |
global public | 292 |
multiorgan failure | 292 |
human rights | 292 |
hospital staff | 292 |
may include | 292 |
mobile phone | 292 |
clinical diagnosis | 292 |
hazard ratio | 292 |
se ha | 292 |
airway management | 291 |
research team | 291 |
pulmonary vascular | 291 |
cancer treatment | 291 |
swab samples | 291 |
per cent | 291 |
cell counts | 290 |
clinical experience | 290 |
clinical deterioration | 290 |
subgroup analysis | 289 |
preliminary results | 289 |
positive result | 289 |
independent variables | 289 |
serum creatinine | 288 |
cerebrospinal fluid | 288 |
study date | 288 |
life satisfaction | 288 |
inflammatory effects | 288 |
college students | 288 |
recently emerged | 288 |
analysis revealed | 288 |
aerosol generating | 288 |
psychological effects | 287 |
following covid | 287 |
chronic lung | 287 |
patients aged | 287 |
comorbid conditions | 286 |
also included | 286 |
severity score | 286 |
hopkins university | 286 |
particularly important | 286 |
decreased mortality | 286 |
healthcare worker | 286 |
serious adverse | 286 |
diagnostic test | 286 |
patient data | 286 |
label non | 286 |
recent reports | 286 |
first day | 286 |
el uso | 286 |
conducted using | 286 |
inflammatory diseases | 286 |
current knowledge | 285 |
elective procedures | 285 |
daily cases | 285 |
negative emotions | 285 |
clinical decision | 285 |
thromboembolic complications | 285 |
lymphocyte counts | 285 |
hiv aids | 285 |
asymptomatic covid | 285 |
google scholar | 284 |
digestive symptoms | 284 |
early warning | 284 |
treat patients | 284 |
deaths due | 284 |
younger age | 283 |
metabolic syndrome | 283 |
psychological support | 283 |
symptomatic covid | 283 |
cardiovascular risk | 283 |
princess cruise | 283 |
asymptomatic infections | 283 |
serological tests | 283 |
unclear whether | 283 |
indicating person | 283 |
recent years | 282 |
higher among | 282 |
analysis based | 282 |
world bank | 282 |
cardiac surgery | 282 |
clinical predictors | 282 |
three groups | 282 |
deep convolutional | 282 |
recovered cases | 282 |
royal college | 282 |
colorectal cancer | 282 |
anticoagulant treatment | 281 |
family member | 281 |
transmission risk | 281 |
retrospective review | 281 |
patient safety | 281 |
similar results | 281 |
care settings | 280 |
city area | 280 |
medical record | 280 |
health disparities | 280 |
data sharing | 280 |
spanish flu | 280 |
coronary syndrome | 279 |
personal fees | 279 |
old woman | 279 |
including sars | 279 |
developed countries | 279 |
cardiac involvement | 279 |
medical services | 279 |
large scale | 278 |
take place | 278 |
effectively inhibit | 278 |
blood flow | 278 |
learning model | 278 |
results obtained | 278 |
related mortality | 278 |
patient characteristics | 278 |
ethical standards | 278 |
patients also | 278 |
chronic pain | 277 |
among individuals | 277 |
clinical suspicion | 277 |
binding affinity | 276 |
previous reports | 276 |
learning models | 276 |
nosocomial transmission | 276 |
total cases | 276 |
virus may | 276 |
race ethnicity | 276 |
patients underwent | 276 |
clinical benefit | 276 |
laboratory parameters | 276 |
reported confirmed | 276 |
health facilities | 276 |
preliminary data | 276 |
journal pre | 276 |
recent report | 276 |
three cases | 275 |
seafood market | 275 |
severe complications | 275 |
pcr assay | 275 |
death cases | 275 |
lower lobe | 275 |
upper limit | 275 |
european centre | 275 |
time point | 275 |
health records | 274 |
marital status | 274 |
age distribution | 274 |
three different | 274 |
may become | 274 |
multivariate logistic | 273 |
molecular mechanisms | 273 |
severe ards | 273 |
stimulating factor | 273 |
adaptive immunity | 273 |
case counts | 272 |
ards patients | 272 |
education level | 272 |
different levels | 272 |
clinical conditions | 271 |
viral spread | 271 |
cognitive impairment | 271 |
one day | 271 |
studies suggest | 271 |
chest radiographs | 271 |
nursing staff | 271 |
individual patient | 271 |
influenza infection | 270 |
underlying medical | 270 |
obese patients | 270 |
sustainable development | 270 |
ethics approval | 270 |
rhesus macaques | 270 |
discharged home | 270 |
community spread | 270 |
therapeutic agents | 270 |
lancet infectious | 270 |
illness onset | 270 |
segment elevation | 269 |
cytokine storms | 269 |
safety profile | 269 |
smoking status | 269 |
may represent | 269 |
reduce covid | 269 |
treatment group | 268 |
clinical efficacy | 268 |
elevation myocardial | 268 |
hospital setting | 268 |
underlying conditions | 268 |
low molecular | 268 |
studies included | 267 |
health concerns | 267 |
mg daily | 267 |
icu care | 267 |
household income | 267 |
clinical manifestation | 267 |
diagnostic criteria | 267 |
qtc prolongation | 267 |
ongoing clinical | 266 |
compared using | 266 |
en las | 266 |
term outcomes | 266 |
like covid | 266 |
specific grant | 266 |
secondary infections | 266 |
insulin resistance | 266 |
two main | 266 |
amino acids | 266 |
pulmonary hypertension | 265 |
reported symptoms | 265 |
transcriptase polymerase | 265 |
preferred reporting | 265 |
prognostic value | 265 |
normally distributed | 265 |
severe clinical | 265 |
analysis clinical | 265 |
prevent covid | 265 |
raw data | 264 |
human subjects | 264 |
reporting items | 264 |
clinical information | 263 |
york state | 263 |
situation reports | 263 |
secondary outcomes | 263 |
reported case | 263 |
influenza vaccination | 263 |
plasma levels | 263 |
therapeutic targets | 262 |
negative effects | 262 |
hiv infection | 262 |
acid detection | 262 |
particulate matter | 261 |
high viral | 261 |
storm syndrome | 261 |
several factors | 261 |
viral proteins | 261 |
receiver operating | 261 |
will increase | 261 |
cell infection | 261 |
significant risk | 261 |
univariate analysis | 260 |
normal distribution | 260 |
specific antibodies | 260 |
uk biobank | 260 |
cell lines | 260 |
blood count | 260 |
approved drugs | 260 |
ventilatory support | 260 |
internal consistency | 260 |
confounding factors | 259 |
like disease | 259 |
significant role | 259 |
will allow | 259 |
signaling pathways | 259 |
index case | 259 |
current status | 259 |
false positive | 259 |
immune dysregulation | 259 |
arterial blood | 259 |
become available | 258 |
reactive oxygen | 258 |
susceptible individuals | 258 |
por sars | 258 |
may reflect | 258 |
early identification | 258 |
potential conflict | 258 |
positively associated | 258 |
old age | 258 |
rheumatic disease | 258 |
sensitivity analyses | 258 |
declared covid | 257 |
study aims | 257 |
chloroquine effectively | 257 |
time interval | 257 |
epidemic curve | 257 |
randomized trials | 257 |
patients using | 257 |
test positive | 257 |
also shown | 256 |
new insights | 256 |
confirmed coronavirus | 256 |
new disease | 256 |
will become | 256 |
glycemic control | 256 |
social contact | 256 |
healthcare resources | 256 |
daily basis | 256 |
intellectual content | 256 |
controlled clinical | 256 |
fatal outcomes | 255 |
protective role | 255 |
disease pneumonia | 255 |
disease onset | 255 |
search strategy | 255 |
economic crisis | 255 |
cardiogenic shock | 255 |
position statement | 255 |
coronavirus epidemic | 255 |
cell receptor | 255 |
point scale | 255 |
help us | 254 |
took place | 254 |
receptor antagonist | 254 |
medical supplies | 254 |
emerged novel | 254 |
influenza vaccine | 253 |
different regions | 253 |
profit sectors | 253 |
human participants | 253 |
induced acute | 253 |
airway epithelial | 253 |
significant decrease | 253 |
essential services | 253 |
age years | 253 |
respiratory pathogens | 253 |
global covid | 253 |
people infected | 252 |
effect size | 252 |
syndrome associated | 252 |
electron microscopy | 252 |
pandemic continues | 252 |
financial interests | 252 |
surface stability | 252 |
treatment guidelines | 252 |
among chinese | 252 |
personal relationships | 252 |
susceptible population | 251 |
spread across | 251 |
racial ethnic | 251 |
search terms | 251 |
may present | 251 |
novel corona | 251 |
associated acute | 251 |
critical disease | 251 |
disease pandemic | 251 |
blood gas | 251 |
male patients | 251 |
home isolation | 250 |
ill adults | 250 |
emerging evidence | 250 |
least days | 250 |
factors may | 250 |
old female | 250 |
oxygen species | 250 |
care resources | 250 |
low dose | 250 |
infected individual | 249 |
sample sizes | 249 |
findings may | 249 |
noninvasive ventilation | 249 |
moderate coronavirus | 249 |
term effects | 249 |
mm hg | 249 |
natriuretic peptide | 249 |
since december | 249 |
infected population | 248 |
minimally invasive | 248 |
red blood | 248 |
among different | 248 |
using spss | 248 |
younger patients | 248 |
statistical computing | 248 |
quarantine measures | 248 |
direct viral | 248 |
requiring hospitalization | 248 |
clinical presentations | 247 |
psychological responses | 247 |
published studies | 247 |
online learning | 246 |
neonates born | 246 |
significantly decreased | 246 |
surgical patients | 246 |
pneumonia clinical | 246 |
health risk | 246 |
operating rooms | 246 |
analysis using | 246 |
based model | 246 |
effective vaccine | 245 |
high quality | 245 |
ct score | 245 |
care personnel | 245 |
pulmonary function | 245 |
large numbers | 245 |
february th | 245 |
kcal mol | 245 |
airway pressure | 244 |
emergency care | 244 |
stroke patients | 244 |
binding site | 244 |
platelet counts | 244 |
antibody testing | 243 |
patients required | 243 |
anxiety among | 243 |
related factors | 243 |
published data | 243 |
results may | 243 |
immediate psychological | 242 |
paving pattern | 242 |
study provides | 242 |
potential conflicts | 242 |
interferon beta | 242 |
community health | 242 |
therapeutic target | 242 |
large sample | 242 |
open source | 242 |
lymphocyte subsets | 242 |
five days | 242 |
surveillance system | 242 |
worse prognosis | 241 |
public places | 241 |
whenever possible | 241 |
concerns regarding | 241 |
position paper | 241 |
attack rate | 240 |
pandemic caused | 240 |
limited access | 240 |
health effects | 240 |
cell culture | 240 |
th percentile | 240 |
level data | 240 |
clinical picture | 240 |
smooth muscle | 240 |
mononuclear cells | 239 |
emergency medicine | 239 |
several days | 239 |
plastic surgery | 239 |
strongly associated | 239 |
distress among | 239 |
comparative study | 239 |
human cells | 239 |
cox regression | 239 |
international committee | 239 |
important factor | 238 |
another important | 238 |
thromboembolic disease | 238 |
previous years | 238 |
en un | 238 |
therapeutic anticoagulation | 238 |
cell response | 238 |
nosocomial infection | 238 |
current crisis | 237 |
vitro antiviral | 237 |
symptomatic cases | 237 |
flow oxygen | 237 |
recently reported | 237 |
online questionnaire | 237 |
chronic medical | 237 |
international society | 237 |
patients covid | 236 |
based analysis | 236 |
high proportion | 236 |
data points | 236 |
must also | 236 |
international travel | 236 |
cytokine levels | 236 |
les patients | 235 |
study shows | 235 |
nasal congestion | 235 |
chinese government | 235 |
symptoms may | 235 |
liver damage | 235 |
multivariable logistic | 235 |
alcohol use | 235 |
clinical condition | 235 |
contact rate | 235 |
highly infectious | 235 |
outpatient clinic | 235 |
health risks | 234 |
measured using | 234 |
illness severity | 234 |
using deep | 234 |
operating characteristic | 234 |
epidemiological studies | 234 |
past medical | 234 |
new infections | 234 |
vitro studies | 233 |
per year | 233 |
new normal | 233 |
promising results | 233 |
drug therapy | 233 |
highly pathogenic | 233 |
crp levels | 233 |
ebola outbreak | 233 |
epub ahead | 233 |
serum samples | 233 |
first weeks | 233 |
patient developed | 233 |
inspired oxygen | 233 |
local health | 232 |
symptoms among | 232 |
publicly reported | 232 |
demographic information | 232 |
higher number | 232 |
age range | 232 |
human resources | 232 |
laboratory test | 232 |
general surgery | 232 |
correlation analysis | 232 |
male gender | 232 |
acute renal | 232 |
showed significant | 232 |
exposure risk | 232 |
median duration | 232 |
standard deviations | 232 |
conspiracy theories | 232 |
widely available | 232 |
additional file | 232 |
fold higher | 231 |
respiratory samples | 231 |
study demonstrated | 231 |
data used | 231 |
major role | 231 |
human lung | 231 |
getting infected | 231 |
pooled analysis | 231 |
risk perceptions | 231 |
broad spectrum | 231 |
among adults | 231 |
mobility data | 231 |
infections among | 231 |
control covid | 231 |
human airway | 230 |
mathematical modelling | 230 |
psychological stress | 230 |
psychiatric disorders | 230 |
case definition | 230 |
health anxiety | 230 |
higher compared | 230 |
potential benefits | 230 |
moving average | 229 |
rapid response | 229 |
likely due | 229 |
rate among | 229 |
people worldwide | 229 |
different stages | 229 |
recent data | 229 |
complement activation | 229 |
unknown etiology | 229 |
control groups | 229 |
platelet activation | 229 |
tracheal intubation | 229 |
may develop | 229 |
animal model | 229 |
lung pathology | 229 |
asian countries | 229 |
high dose | 228 |
elderly population | 228 |
fulminant myocarditis | 228 |
cov infections | 228 |
different clinical | 228 |
hemophagocytic lymphohistiocytosis | 228 |
including patients | 228 |
reduce mortality | 228 |
viral disease | 227 |
seven patients | 227 |
national level | 227 |
hospitalization rates | 227 |
differential equations | 227 |
effects model | 227 |
peer reviewed | 226 |
excess deaths | 226 |
lymph nodes | 226 |
time frame | 226 |
drug use | 226 |
understanding sars | 226 |
without diabetes | 226 |
time periods | 226 |
school closure | 226 |
identify patients | 226 |
allows us | 226 |
admitted patients | 225 |
hypertensive patients | 225 |
therapeutic efficacy | 225 |
ejection fraction | 225 |
specific treatment | 225 |
ibd patients | 225 |
resonance imaging | 225 |
cell type | 225 |
mask use | 225 |
including age | 225 |
lung changes | 224 |
hypoxemic respiratory | 224 |
among medical | 224 |
isolation ward | 224 |
research priorities | 224 |
older individuals | 224 |
moderate disease | 223 |
disease may | 223 |
interactive web | 223 |
high degree | 223 |
del paciente | 223 |
th cells | 223 |
surg doi | 223 |
complete blood | 223 |
emergency medical | 223 |
prediction model | 223 |
first report | 222 |
abo blood | 222 |
expert opinion | 222 |
ischaemic stroke | 222 |
pulmonary artery | 222 |
fatal outcome | 222 |
patients clinical | 222 |
influenza viruses | 222 |
expert group | 222 |
dental care | 222 |
reasonable request | 222 |
anxiety disorders | 221 |
model based | 221 |
pivotal role | 221 |
psychometric properties | 221 |
initial symptoms | 221 |
inflammatory state | 221 |
prediction models | 221 |
shed light | 221 |
stock market | 221 |
reduced mortality | 221 |
population health | 221 |
care facility | 221 |
treatment protocol | 221 |
altered mental | 220 |
general health | 220 |
research questions | 220 |
significant proportion | 220 |
severe form | 220 |
structural basis | 220 |
stress levels | 220 |
antibody tests | 220 |
oral health | 220 |
data obtained | 219 |
data show | 219 |
allowed us | 219 |
pandemic outbreak | 219 |
angiotensin i | 219 |
year old | 219 |
protein levels | 219 |
cases may | 219 |
becoming infected | 219 |
viral nucleic | 219 |
early march | 218 |
newly diagnosed | 218 |
throat swabs | 218 |
ethnic groups | 218 |
early experience | 218 |
economic growth | 218 |
strongly agree | 218 |
becomes available | 218 |
requiring intensive | 218 |
deep neural | 218 |
novel covid | 218 |
alcohol consumption | 218 |
current literature | 218 |
negative test | 218 |
partial thromboplastin | 218 |
protective effects | 218 |
dental practice | 218 |
negative correlation | 217 |
beneficial effect | 217 |
herpes simplex | 217 |
function tests | 217 |
special attention | 217 |
severe anxiety | 217 |
model using | 217 |
depression symptoms | 217 |
prospective observational | 217 |
patients whose | 217 |
gastrointestinal manifestations | 216 |
energy consumption | 216 |
center experience | 216 |
week period | 216 |
related complications | 216 |
social network | 216 |
outcome measures | 216 |
track covid | 216 |
east asia | 216 |
countries like | 215 |
doubling time | 215 |
primary endpoint | 215 |
timely manner | 215 |
inactive inactive | 215 |
care setting | 215 |
daily number | 215 |
ct image | 215 |
covid positive | 215 |
clinical settings | 215 |
medical professionals | 215 |
emergency surgery | 215 |
people may | 214 |
nuclear factor | 214 |
countries around | 214 |
ace levels | 214 |
emerging coronaviruses | 214 |
high flow | 214 |
one third | 214 |
ct manifestations | 214 |
stay home | 214 |
high expression | 214 |
global spread | 214 |
indirect effects | 214 |
first line | 214 |
sin embargo | 214 |
affiliations key | 213 |
new data | 213 |
covid cases | 213 |
ethnic minority | 213 |
disease outcomes | 213 |
also suggested | 213 |
best practice | 213 |
natural disasters | 213 |
may benefit | 213 |
spread worldwide | 212 |
remains unknown | 212 |
american heart | 212 |
joint mission | 212 |
may vary | 212 |
ncov outbreak | 212 |
fatal cases | 212 |
multiple myeloma | 212 |
lung lesions | 212 |
receptor recognition | 212 |
thromboplastin time | 212 |
home quarantine | 212 |
one another | 211 |
less common | 211 |
will lead | 211 |
patients tested | 211 |
orf ab | 211 |
renal injury | 211 |
mortality associated | 211 |
cancer surgery | 211 |
previously published | 211 |
spinal cord | 211 |
olfactory bulb | 211 |
including il | 211 |
close monitoring | 211 |
dans le | 211 |
epidemic model | 210 |
detailed information | 210 |
migrant workers | 210 |
life support | 210 |
current data | 210 |
chronic inflammation | 210 |
laboratory values | 210 |
heart association | 210 |
lung parenchyma | 210 |
available resources | 210 |
dipeptidyl peptidase | 210 |
glucose levels | 210 |
protein kinase | 210 |
anticoagulant therapy | 210 |
international spread | 210 |
positive patient | 210 |
vulnerable population | 210 |
following criteria | 210 |
positive airway | 209 |
antibody titers | 209 |
orthopaedic surgeons | 209 |
cells via | 209 |
service delivery | 209 |
stroke care | 209 |
existing literature | 209 |
contact history | 209 |
congenital heart | 209 |
based survey | 209 |
personal hygiene | 209 |
serum ferritin | 208 |
home order | 208 |
ethnic disparities | 208 |
inflammatory cells | 208 |
positive pressure | 208 |
rna detection | 208 |
aerosol transmission | 208 |
may influence | 208 |
also help | 208 |
fight covid | 208 |
last days | 208 |
every patient | 207 |
secondary bacterial | 207 |
weight loss | 207 |
social sciences | 207 |
include fever | 207 |
disease activity | 207 |
randomly selected | 207 |
hydrogen peroxide | 207 |
online version | 207 |
medical imaging | 207 |
outpatient clinics | 207 |
oral cavity | 207 |
flow cytometry | 207 |
funding agencies | 207 |
also present | 206 |
breast milk | 206 |
infectious agents | 206 |
wuhan university | 206 |
comprehensive review | 206 |
killer cells | 206 |
therapeutic option | 206 |
total deaths | 206 |
remote monitoring | 206 |
adverse reactions | 206 |
lavage fluid | 206 |
risk communication | 206 |
hospital resources | 206 |
dengue virus | 205 |
three weeks | 205 |
factors related | 205 |
save lives | 205 |
novel severe | 205 |
psychological well | 205 |
like receptors | 205 |
data protection | 205 |
room temperature | 205 |
clinical setting | 205 |
expert panel | 205 |
oropharyngeal swabs | 205 |
natural history | 205 |
symptoms onset | 205 |
gut microbiota | 204 |
data availability | 204 |
interstitial lung | 204 |
pediatric covid | 204 |
west africa | 204 |
severe lung | 204 |
significant correlation | 204 |
potential risks | 204 |
presenting symptoms | 204 |
detect covid | 204 |
clinically relevant | 204 |
two independent | 204 |
health condition | 204 |
clinical implications | 204 |
commonly reported | 204 |
interval prolongation | 204 |
psychiatric symptoms | 204 |
negative affect | 204 |
en charge | 204 |
since march | 204 |
common among | 203 |
higher odds | 203 |
global economy | 203 |
based dashboard | 203 |
author contributions | 203 |
systematic literature | 203 |
series analysis | 203 |
rapidly changing | 203 |
appropriate ppe | 203 |
skeletal muscle | 203 |
initial phase | 203 |
studies reporting | 203 |
growth rates | 203 |
english language | 202 |
patients recovered | 202 |
eight patients | 202 |
well established | 202 |
atypical pneumonia | 202 |
prime minister | 202 |
local transmission | 202 |
asymptomatic transmission | 202 |
studies conducted | 202 |
second week | 202 |
requiring icu | 202 |
specific covid | 202 |
immune systems | 202 |
particularly vulnerable | 202 |
network analysis | 202 |
surge capacity | 202 |
medical community | 202 |
telehealth services | 202 |
antiviral effect | 201 |
radiology department | 201 |
patients might | 201 |
cell subsets | 201 |
close proximity | 201 |
viral spike | 201 |
private sector | 201 |
tongji hospital | 201 |
coronavirus replication | 201 |
taste disorders | 201 |
managing covid | 201 |
bibliometric analysis | 201 |
two consecutive | 201 |
case data | 201 |
transmission rates | 201 |
life cycle | 201 |
italian society | 201 |
studies involving | 201 |
mild moderate | 201 |
china joint | 201 |
also considered | 201 |
mechanisms underlying | 201 |
gas exchange | 201 |
studies will | 201 |
wide variety | 200 |
failure assessment | 200 |
pandemic preparedness | 200 |
national lockdown | 200 |
provide information | 200 |
healthy volunteers | 200 |
significant effect | 200 |
transmission routes | 200 |
significant changes | 200 |
hospital capacity | 200 |
medical sciences | 200 |
res doi | 200 |
large proportion | 199 |
optimal control | 199 |
inhibit sars | 199 |
population level | 199 |
i ifn | 199 |
nan sha | 199 |
radiographic findings | 199 |
global burden | 199 |
cov spike | 199 |
significance level | 199 |
diseases society | 199 |
like illness | 199 |
ambient air | 199 |
clinical samples | 199 |
epidemic spread | 199 |
standard errors | 199 |
infection covid | 199 |
carrier transmission | 199 |
severe influenza | 199 |
competing financial | 198 |
sleep disturbance | 198 |
past days | 198 |
phase trial | 198 |
drug development | 198 |
death due | 198 |
older persons | 198 |
cell lung | 198 |
different time | 198 |
review article | 198 |
increased susceptibility | 198 |
three main | 198 |
will take | 198 |
antibody test | 198 |
sars pathogenesis | 198 |
moderate cases | 198 |
medical centers | 197 |
combat covid | 197 |
care team | 197 |
physical symptoms | 197 |
detection rate | 197 |
days post | 197 |
care hospital | 197 |
perceived social | 197 |
endoplasmic reticulum | 196 |
several clinical | 196 |
secondary infection | 196 |
preventive behaviours | 196 |